Sacral tumors are rare. Appropriate surgical resection is crucial to treat the disease while minimizing disease recurrence. We present the results of 93 patients with sacral tumors to analyze the long-term functional and oncological results of patients undergoing en bloc resection. The medical data between January 2003 and July 2010 was retrospectively reviewed. None of the 93 patients died intra-or postoperatively. Patients undergoing intralesional curettage (range, 6500-25,000 mL; mean, 13,500 mL) lost more blood than those patients with wide excision (range, 1000-8100 mL; mean, 3590 mL). Mean follow-up duration from the time of surgery until most recent clinic visit or death was 44.5 months (range, 6-105 months). This study is an educational tool regarding primary sacral tumors and provides evidence on the treatment. It presents results from a large group of patients with sacral tumor. After follow-up, we did not fi nd that sacrifi ced nerve roots and surgical margins have an impact on the recurrence of the tumor. Patients undergoing intralesional curettage lost more blood than those patients with wide excision. Postoperative bladder/bowel dysfunction was more severe for patients with removal of S1 and S2.
Sacral tumors are rare. Appropriate surgical resection is crucial to treat the disease while minimizing disease recurrence. We present the results of 93 patients with sacral tumors to analyze the long-term functional and oncological results of patients undergoing en bloc resection. The medical data between January 2003 and July 2010 was retrospectively reviewed. None of the 93 patients died intra-or postoperatively. Patients undergoing intralesional curettage (range, 6500-25,000 mL; mean, 13,500 mL) lost more blood than those patients with wide excision (range, 1000-8100 mL; mean, 3590 mL). Mean follow-up duration from the time of surgery until most recent clinic visit or death was 44.5 months (range, 6-105 months). This study is an educational tool regarding primary sacral tumors and provides evidence on the treatment. It presents results from a large group of patients with sacral tumor. After follow-up, we did not fi nd that sacrifi ced nerve roots and surgical margins have an impact on the recurrence of the tumor. Patients undergoing intralesional curettage lost more blood than those patients with wide excision. Postoperative bladder/bowel dysfunction was more severe for patients with removal of S1 and S2. S acral tumor is relatively rare and accounts for approximately 1 in 40,000 hospital admissions. 1 The diffi culty in diagnosing at the onset is due to a deceptive manifestation. Unfortunately, the tumor is often large when it is defi nitively diagnosed, which makes surgery challenging. Surgical margin or intralesional curettage does not have a radical effect on sacral malignant tumor, benign tumor, or progressivity tumor (such as giant cell tumor) with a high relapse rate at the local hospital. 2 Radical excision, such as partial or total sacrectomy, has satisfactory treatment effectiveness. 3, 4 However, the intraoperative and postoperative complications including neurological compromise, visceral injury or resection, infection, vascular injury, and severe soft tissue removal threaten the patient's life and the quality of life. [5] [6] [7] This article reviews the clinical data on patients with sacral tumor resection to analyze the long-term functional and oncological results of patients undergoing en bloc resection.
MATERIALS AND METHODS
The medical database of our hospital between January 2003 and July 2010 was retrospectively reviewed. Patients were included if the diagnosis was primary sacral tumor, there was no history of prior surgical treatments other than needle biopsy, and there was a minimum of 6 months clinical follow-up. Ninety-three patients with sacral tumor were identifi ed. The data, including patient age, sex, histologic characteristics of primary tumor, neural symptom, surgery technique, level of nerve roots sacrifi ced, surgical margins, and estimated blood loss were reviewed.
Preoperative evaluation consisted of neurologic examination, sampling biopsy, computed tomography scan, magnetic resonance imaging, abdominal ultrasonography, and 99mTc total body bone scan. All patients underwent preoperative digital subtraction angiography to visualize relationships with internal iliac, midsacral and gluteal arteries, and local gelfoam blood vessels embolotherapy was performed.
Surgical margins were grouped as wide, contaminated, or intralesional resections based on the intraoperative fi ndings by the senior surgeon (Z.Z.) and the histopathological examination of the excised tumor specimens. Functional outcomes were determined by analyzing the patients' bladder and bowel functions at 6-month follow-up.
RESULTS

General Data, Follow-Up Course, and Blood Loss
The present study consists of 93 consecutive patients who underwent primary en bloc excision of sacral tumor. The study included 48 men and 45 women with ages ranging from 12 to 86 years (mean, 45.1 years). Characteristics of surgical procedures are displayed in Table 1 .
All patients were routinely applied tumor-related blood vessel embolism by digital subtraction angiography technique. Twentyfi ve patients were treated with a posterioronly approach to remove the tumor. Sixty patients underwent a sacrectomy with staged anterior and posterior procedures to achieve en bloc tumor excision. Eight patients were treated with abdomino-anterior approach to remove the tumor. Twenty-six patients of the 67 lesions treated with wide excision, margins were adequate in 52 patients. Surgical margins were intralesional in 5 patients, and contaminated in 10 patients were contaminated. These 15 patients were considered to have inadequate/positive margins. Thus, the overall success rate of achieving our goal of wide en bloc tumor excision was 77.6% in this study.
None of 93 patients died intra-or postoperatively. The intraoperative blood loss ranged from 1000 to 25,000 mL (average, 7250 mL) ( Table 2 ). Twenty-fi ve patients treated with a posterior-only approach lost blood ranging from 1300 to 16,800 mL (mean, 6200 mL), 60 patients with anterior and posterior procedures lost 1000 to 22,500 mL (mean, 7400 mL), and 8 patients with abdomino-anterior approach lost 1600 to 25,000 mL (mean, 10,600 mL). In patients undergoing curettage, intraoperative blood loss ranged from 6500 to 25,000 mL (mean, 13,500 mL). In patients with wide excision, intraoperative blood loss ranged from 1000 to 8100 mL (mean, 3590 mL). Our analysis found improvement of disease-free survival in patients with wide en bloc tumor margins compared to those with contaminated or intralesional margins. Age, sex, and nerve roots sacrifi ced had no statistically signifi cant impact on the recurrence (Table 3) . At the time of analysis, local recurrence was statistically signifi cantly affected by a wide surgical margins (Pϭ0). Of the 52 patients with wide margins 45 (86.5%) had no evidence of disease, and they had a mean diseasefree survival of 40.5 months (range, 6-93 months). However, 60.0% (6/10) of those patients with contaminated margins were alive with disease who had mean diseasefree survival of 45. Regarding histopathological diagnosis, 28 of the tumors were diagnosed as giant cell tumor of bone (30.1%), 40 as chordoma (43.0%), 14 as malignant neurogenic tumor (15%), 4 as benign neurogenic tumor (4.3%), 4 as hemangiopericytoma (4.3%), 3 as malignant fi brous histiocytoma (3.2%), and 4 as malignant teratoma (4.3%).
Pre-and Postoperative Functional Outcomes
Postoperative functional outcomes in this study were determined by assessing the patients' bladder and bowel functions 6 months postoperatively. All 32 patients who presented with loss of bladder and bowel control had no control after surgery. Of the 61 patients who had intact bladder and bowel control preoperatively, 27 patients (44.3%) experienced postoperative bowel and/or bladder dysfunction, and 34 patients (36.6%) in this study had normal bladder and bowel functions at 6 months. However, the remaining 63.4% of the patients had either partial or complete loss of bladder or bowel functions. The postsurgical bladder and bowel function was correlated with intraoperative nerve root excised (Table 4) .
Among the 61 patients who had intact bladder and bowel control preoperatively, all 4 patients with S1, and below nerve roots excised lost normal control of urinary and bowel continence, and 4 of 18 patients with S2 and below roots excised, 22 of 31 patients retained normal urinary and bowel continence, and 22 of 35 patients retained S3 and below roots excised, and all 8 patients S4 roots excised had normal urinary and bowel function (Table 4) .
DISCUSSION
Most of original clinical situations of sacral tumor were pain in the sacrococcygeal region, sometimes accompanied by pseudo or true root radiating pain, and subsequent sense-movement disorder of It is diffi cult to detect early the sacral tumor and the skeletal destruction on plain radiographs because celiac organs overlap with vicinal bones. As the structure of the pelvis covered the lump, sacral tumor is easy to be confused with lumbar or cavitas pelvis tumors. 8 Once defi nitely diagnosed, these tumors are large and extensively involved leading to diffi cult treatment. Although wide excision is the best choice for sacral tumor until now, resulting in good local control and extension of the patient's survival, it often means a determinate operative mortality and higher complications due to the complicated adjacent structure of the sacral tumor. Intraoperative hemorrhage, nerve root and plexus injury, wound complications and lumbar vertebrae pelvis-reconstruction complications are as challenging as local tumor recurrence of the sacral tumor resection. 7 The main blood supply of the sacrum is the bilateral internal iliac artery and the median sacral artery. Due to the short distance between the tumor and these vessels, there is often severe intraoperative blood loss. In the present study, intraoperative blood loss ranged from 1000 to 25,000 mL (mean, 7250 mL), which is similar to previously published studies. [8] [9] [10] Approximately 1300 to 16,800 mL (mean, 6200 mL) blood was lost in the 25 patients undergoing posterior surgery, 1000 to 22,500 mL (mean, 7400 mL) in the 60 patients undergoing anterior and posterior surgery, and 1600 to 25,000 mL (mean, 10,600 mL) in the 8 patients undergoing abdomino-anterior surgery. In 26 patients undergoing curettage, intraoperative blood loss ranged from 6500 to 25,000 mL (mean, 13,500 mL). In 67 patients with wide excision, intraoperative blood loss ranged from 1000 to 8100 mL (mean, 3590 mL).
It is well known that the primary treatment of sacral tumor is surgical resection.
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Several factors infl uence local recurrence after the removal of these tumors. Among them, tumor location is the most important factor in recurrence, as statistically signifi cant differences were found between sacral tumor located at or below S3 and located above S3. 12 However, we did not fi nd these differences. Among 50 patients with tumors located above S3, 18 patients had recurrence, and 17 of 43 patients with tumors at S3 and below had recurrence. In addition, age, sex, and surgical margins had no statistically signifi cant impact on the recurrence.
The postoperative local recurrence rate is directly related to the scope and degree of the resection. 3, 11, [13] [14] [15] [16] In the our study, 11 of the 37 patients had a wide margin, 11 of which experienced recurrence (29.7%); 21 patients had a perilesional resection, 9 of which experienced recurrence (42.8%); 35 patients had a contaminated excisions, 15 of which experienced recurrence (42.8%). Although we applied tumor-related blood vessel embolism using digital subtraction angiography technique, we did not fi nd a lower recurrence rate for radical resections.
Sectioning of the S1, S2, and S3 nerve roots may result in bladder and bowel disability. Patients in whom all sacral nerve roots have been sacrifi ced also experienced complete bladder and bowel dysfunction. Postoperative functional outcomes including bladder and bowel functions were assessed 6 months postoperatively. We found that 27 of 61 patients with intact bladder and bowel control preoperatively experienced postoperative bowel and/or bladder dysfunction at 6 months. Postoperative bladder/bowel dysfunction was more severe for patients with removal of S1 and S2 (only 4 had normal urinary or bowel function).
Within the spine, chordoma is the most common primary tumor of the sacrum, and giant cell tumor is the second most common. 15 Randall et al 16 found chordoma was the most common primary tumor (6 patients). Other diagnoses included chondrosarcomas (3), osteosarcoma (3), Ewing's sarcoma (3), malignant peripheral nerve sheath tumor (2), metastatic adenocarcinomas (2), fi brosarcoma (1), hemangiopericytoma (1), monophasic synovial sarcoma (1), lymphoma (1), ependymoma (1), and hibernoma (1). In our study, most patients were diagnosed with giant cell tumor and chordoma with histopathological diagnosis. Twenty-eight patients had giant cell tumor of bone (30.1%), and 40 chordoma (43.0%). Other diagnoses included malignant neurogenic tumor (14) , benign neurogenic tumor (4), hemangiopericytoma (4), malignant fi brous histiocytoma (3), and malignant teratoma (4) .
Among the 26 patients with intralesional excision, only 6 patients had no evidence of disease, 76.9% suffered from recurrence, and 8 patients died from disease. The recurrence rate was higher than Turcotte et al 17 reported, which was 33%. This may be due to the fact that there were various type of tumors in these 26 patients: consisted of 15 chordoma (11 cases of recurrence), 5 giant cell tumor (4 cases of recurrence), 1 hemangioendothelioma (died from disease), 2 malignant fi brous histiocytoma (1 patient died from disease), and 3 malignant neurogenic tumor (2 cases of recurrence).
Our study has several limitations. It is a retrospective review. Although we have collected data of 93 patients, a relative large number, the pool of patients from several centers represents with varying malignant and benign pathologies. The duration of follow-up is relatively short (range, 6-105 months), which might affect the conclusions drawn. In addition, we could not review enough data of sexual function and motor function.
Despite these shortcomings, this study can help us to understand primary sacral tumors and provide some evidence on the treatment. It presents results from a large group of patients with sacral tumor. After follow-up, sacrifi ced nerve roots and surgical margins were not found to have an impact on the tumor recurrence. Patients undergoing intralesional curettage lost
